Ongoing Trades #5 – RZLV & ALKS Position Review October 2025
Company Overview – Rezolve AI (NASDAQ: RZLV)
Rezolve AI is an AI-driven commerce platform that integrates real-time consumer engagement with mobile payment technology. The company’s core mission is to enable “Commerce in the Moment”, allowing brands to interact with customers instantly through predictive data and contextual triggers.
Rezolve’s main technologies include the Predictive AI Engine and Engagement Commerce System, which provide faster decision-making and highly personalized marketing execution compared to traditional e-commerce platforms. By analyzing user location, behavior, and intent in real time, Rezolve enables merchants to deliver targeted promotions and frictionless purchase experiences.
As of 2025, the company is expanding primarily across Europe and Asia, building a scalable B2B partnership network with major retail and payment providers. With the global shift toward AI-powered digital transactions, Rezolve’s strategy of combining mobile payments and real-time marketing positions it as a key innovator in next-generation commerce infrastructure.
Company Overview – Alkermes (NASDAQ: ALKS)
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) disorders and oncology indications. Its key commercial products include ARISTADA® for schizophrenia and VIVITROL® for alcohol and opioid dependence.
The company continues to advance its pipeline targeting high unmet medical needs, including narcolepsy, hypersomnolence, and major depressive disorder. Its latest clinical spotlight is ALK S2680 (Vibrance-1), a Phase 2 candidate designed to treat excessive daytime sleepiness.
Clinical data from this program will be presented at the World Sleep Congress 2025 in Singapore. The announcement has raised investor expectations, as the results could redefine therapeutic approaches within the sleep-disorder market. These developments reinforce Alkermes’ growing presence as a long-term innovator in the CNS therapeutics landscape.
Ongoing Trades – RZLV & ALKS Position Review
RZLV (Rezolve AI PLC)
Trade Summary
Average Entry: 3.03
Target: 8.4
Executed: 4.32 (1st partial, 40%) / 6.79 (final exit)
Current Status
On September 30, the stock marked a low at 4.70 and a close at 4.98, confirming a short-term base.
The range between the low and close has been set as the buying zone, with plans to re-enter gradually if price revisits this area.
Recent pullback shows declining volume, indicating consolidation and absorption rather than panic selling.
The structure suggests potential support confirmation followed by a recovery attempt,
with the possibility of replicating the previous strong upward swing.
Trading Plan
Buying Range: 4.70–4.98
Target: 8.4
Strategy: Avoid chasing. Re-enter only upon liquidity confirmation near support.
ALKS (Alkermes PLC)
Trade Summary
1st Entry: 30
Accumulation Zone: 28–30
Stop Zone: 27
Target: 36.45
Execution Timeline
Sep 3: First entry at 30
Sep 8: Broke below stop, made a new low at 25.17 → no stop triggered
Sep 8: Added second position at 25.57, the previous April low
Sep 29: Confirmed rebound and entered third position at 29
Rationale
Since the initial position size was light, I opted for averaging down near structural support instead of a hard stop.
This allowed better cost-basis management and preserved risk balance.
Currently, the price is testing resistance around 32.3,
and a confirmed breakout above this level opens room toward 36.45.
Short-term consolidation remains possible before continuation.
Trading Plan
Hold as long as 30.4 support holds
Add on dips near 29
1st Target: 32.3
2nd Target: 36.4
Stop: 26.5
Ongoing Trades Q&A
1. When RZLV retests the 4.7–4.9 range, what key signals should be confirmed?
The most critical factor is whether a hammer-type candle with a lower shadow appears. During a retest of the support zone, the 1-hour volume profile must show sufficient activity. Rather than entering impulsively during intraday volatility, I plan to observe how the candle closes — focusing on the shape and volume at the closing price — and initiate entries only near the close if conditions align.
2. What is the rationale behind the 8.4 target for RZLV?
The 8.4 level represents a technical rebound zone targeting the previous high. However, beyond the chart structure, RZLV is also engaging in aggressive acquisitions for expansion. This signals a period of business scaling, which could trigger renewed market interest. In other words, this target is not just a technical projection but also reflects fundamental growth momentum that may attract buyers.
3. If ALKS fails to break above the 32 resistance zone, what is the plan?
If the breakout attempt fails, I intend to trim partial profits and prepare for re-entry at lower levels. The recent low-buy entries in ALKS were not driven by any specific news catalyst — they were based on the assumption that shares were rotating between hands, indicating possible accumulation. This is a speculative positioning focused on supply–demand shifts, not fundamental conviction.
4. Could ALKS’s recent rebound signal the start of a new uptrend?
It’s difficult to be certain. The recovery appears to be a technical rebound driven more by market liquidity rotation than by strong buying conviction. Until clear signs of trend reversal emerge, I plan to keep exposure limited and focus on range-based tactical trading rather than directional conviction.
5. Why are both RZLV and ALKS showing rebound patterns after correction?
The current market is liquidity-rich — capital is rotating aggressively across sectors. In this kind of environment, any stock with a valid catalyst can rally sharply. Both RZLV and ALKS are responding to this rotation-driven liquidity flow, and I expect similar setups to continue as part of broader market cycles. Going forward, I’ll focus on identifying stocks with both structural setups and active catalysts to capture momentum during these rotation phases.
Ongoing Trades – Reference Link
Internal Links
External Links
- Rezolve AI – Investor Relations
- RZLV Stock Quote – Yahoo Finance
- Alkermes – Investor Relations
- Alkermes – Research & Development Pipeline
The sentences might sound awkward, but the content is 100% my own experience and thoughts.
It reads like AI? so what?
This blog is written for personal investment journaling and self-reflection only.
The content does not constitute financial advice, investment recommendations, or solicitations of any kind.
All opinions expressed are strictly personal views.
Trading and investing involve risks, including the possible loss of principal.
Any decision to trade or invest should be made solely at your own discretion and responsibility.